do not combine glp-1 receptor agonists with dpp-4 inhibitors guideline and GLP-1RAs: cardiovascular safety and benefits Molecular Insights into the Potential

Annu Rev Neurosci

Thus, only patients with a single weight loss intervention between the initial and follow-up 24-hour urine collections were included in the study

Here is what it does: Tells your pancreas to release insulin, which lowers blood sugar Slows how fast your food leaves your stomach, so you feel full longer Sends signals to your brain to reduce feelings of hunger Some weight-loss and diabetes medications are called GLP-1 receptor agonists, which means they copy this natural hormone and boost its effects

Releases Reminder: WADAs 2025 Prohibited List comes into force on 1 January Further to our communication on 25 September 2024, the World Anti-Doping Agency (WADA) wishes to remind stakeholders that the 2025 List of Prohibited Substances and Methods (List) and the 2025 Monitoring Program come into force on 1 January 2025

In people with obesity, 36 weeks of orforglipron (doses ranging from 12 to 45 mg in a phase 2 trial) resulted in a dose-dependent WL up to 14.7% compared to 2.3% with placebo, with concomitant improvement in cardiometabolic risk factors (Table 2) [25]

I dont have the scientific evidence to prove it (yet), but as I look at the extreme side effects many people experience (nausea, fainting, pancreatitis, dampening reward systems, gas, etc.) its clear to me that the drugs are fighting the natural order of how our bodies function and I have major concerns for how this will impact us in ways we dont yet see